Amicus Therapeutics Reaches Profitability Milestone in Q3 2025

The biotechnology firm Amicus Therapeutics has achieved a significant financial breakthrough, reporting its first GAAP profit in years during the third quarter of 2025. This specialist in rare disease treatments reached profitability amid substantial revenue expansion, potentially signaling a sustained upward trajectory for its shares.

Amicus Therapeutics demonstrated impressive commercial performance across its key therapeutic offerings. Total revenue climbed 17% to $169.1 million, driven by strong results from both established and newer treatments.

The company’s flagship product Galafold recorded a 15% increase in sales, while the Pompe disease therapy combination of Pombiliti + Opfolda saw remarkable growth, surging 45% during the quarter. This balanced performance across the product portfolio underscores the company’s Read more...